---
title: Sound waves reduce movement stiffness
nct_id: NCT07207122
phase: NA
status: RECRUITING
sponsor: Sanmai Technologies PBC dba Sanmai
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07207122"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07207122"
last_fetched: "2026-05-12T14:01:56.523Z"
source: "Parkinson's Pathways (curated)"
---
# Sound waves reduce movement stiffness

**Goal (in five words):** Sound waves reduce movement stiffness

**Official Title:** Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease

**Trial ID:** [NCT07207122](https://clinicaltrials.gov/study/NCT07207122)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Sanmai Technologies PBC dba Sanmai
- **Target Enrollment:** 60 participants
- **Start Date:** 2025-10-08
- **Completion Date:** 2026-12
- **Conditions:** Parkinson Disease
- **Interventions:** Gen0Bh Transcranial Focused Ultrasound System (Active), Gen0Bh Transcranial Focused Ultrasound System (Sham)
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to see whether noninvasive focused ultrasound can improve both motor symptoms and thinking in people with Parkinson's, using motor scores and cognitive tests as main outcomes. The approach uses the Gen0Bh transcranial focused ultrasound system, which sends low‑intensity, focused sound waves through the skull to temporarily change how neurons fire in targeted brain regions, and participants are randomized to active or sham stimulation. It is tested as an add-on to standard dopaminergic therapy like levodopa, so it does not replace your medications and may help with responsiveness or OFF-period severity if effective. The trial is looking for adults 22 to 80 with idiopathic Parkinson's, an OFF-state MDS-UPDRS Part III score of at least 25, stable dopaminergic meds for 30 or more days, MoCA 23 or above, and no prior DBS, seizures, major psychiatric illness, or MRI/ultrasound contraindications.

## Eligibility

- **Minimum age:** 22 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Adults aged 22 to 80 years.
* Diagnosis of idiopathic Parkinson's disease.
* MDS-UPDRS Part III score ≥25 in OFF-medication state at baseline.
* Stable dopaminergic therapy for at least 30 days prior to enrollment.
* English proficiency.
* Normal or corrective hearing and vision.
* Ability to provide informed consent (or availability of an LAR) and comply with protocol requirements.

Exclusion Criteria:

* Atypical or secondary Parkinsonism.
* Prior deep brain stimulation or intracranial surgery.
* MoCA score \<23.
* Severe psychiatric illness (e.g., psychosis, suicidality, untreated major depression).
* History of seizure or intracranial pathology.
* Significant neurologic disease (e.g. brain tumor, multiple sclerosis)
* Contraindication to MRI or ultrasound.
* Unstable systemic medical conditions.
* Active malignancy or history of cancer within the past 5 years.
* Pregnancy or breastfeeding.
* Participation in another interventional trial.
```

## Locations (2)

- The Regenesis Project, Santa Monica, California, United States _(34.0195, -118.4914)_
  - Sheena Tan — (CONTACT) — 310-829-5968 — stan@theneuroassociates.com
  - Kevin Enemuo — (CONTACT) — 310-829-5968 — kenemuo@theneuroassociates.com
  - Sheldon E Jordan, MD, FAAN — (PRINCIPAL_INVESTIGATOR)
- Radial Midtown Manhattan, New York, New York, United States _(40.7143, -74.0060)_
  - Angelique Lucien — (CONTACT) — 929-346-4317 — ask@meetradial.com
  - Ahmed Tahseen, M.D — (CONTACT) — (516) 908-8540 — ahmed@meetradial.com
  - Owen Muir, M.D — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Clinical Team — (CONTACT) — 408-455-3817 — clinical@sanm.ai

---

*Canonical: https://parkinsonspathways.com/trial/NCT07207122*  
*HTML version: https://parkinsonspathways.com/trial/NCT07207122*  
*Source data: https://clinicaltrials.gov/study/NCT07207122*